(Arg)9 acetate (Synonyms: Nona-L-arginine acetate; Peptide R9 acetate) |
カタログ番号GC66389 |
(Arg)9 (ノナ-L-アルギニン) アセテートは、9 つのアルギニン残基で構成される細胞透過性ペプチド (CPP) です。 (Arg)9 アセテートには神経保護特性があり、グルタミン酸モデルで 0.78 μM の IC50 で神経保護活性を示します。
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
IC50: 0.78 μM (neuroprotection)[1]
(Arg)9 (Nona-L-arginine) acetate is a cell-penetrating peptide (CPP) made up of 9 arginine residues. (Arg)9 acetate has neuroprotective property, exhibits neuroprotective activity with an IC50 of 0.78 μM in the glutamic acid model[1][2].
(Arg)9 (Nona-L-arginine; 5-10 μM) acetate provides significant neuroprotection in a dose-response manner following glutamic acid exposure (IC50=0.78 μM). Following kainic acid exposure, (Arg)9 acetate is neuroprotective, but less effective than in the glutamic acid model (IC50=0.81 μM). (Arg)9 acetate also shows neuroprotection following in vitro ischemia (IC50=6 μM)[1].
(Arg)9 (Nona-L-arginine; 1 μM/kg (600 μL); i.v.; once, for 30min; male Sprague-Dawley ratspermanent middle cerebral artery stroke model) acetate shows neuroprotective effects and reduces infarct volume[2].
Animal Model: | Male Sprague-Dawley rats (270 to 320 g) permanent middle cerebral artery stroke model[2] |
Dosage: | 1 μM/kg (600 μL) |
Administration: | Intravenous injection; once, over 5 minutes |
Result: | Reduced significantiy 20% in infarct volume. |
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *